Ask VialBase
Enforcement action · state boards of pharmacy, attorneys general

State-Level Peptide Enforcement Actions (2025-2026) — VialBase News

Last updated · January 1, 2025

State-Level Peptide Enforcement Actions (2025-2026)

Summary

While federal enforcement (FDA, DOJ) drove the headline actions of 2025-2026, state-level regulators independently tightened peptide enforcement across multiple jurisdictions. Ohio, California, Florida, and Texas each took distinct approaches — from pharmacy board consent orders to new disclosure legislation to license suspensions. State attorneys general also stepped into the GLP-1 enforcement gap, targeting telehealth firms and compounders within their borders.

Background

Ohio

Ohio’s Board of Pharmacy was among the most active state regulators:

  • Late 2025 - Early 2026: At least three Ohio pharmacies received consent agreements and fines for peptide compounding violations
  • January 2026: A Columbus-area compounding pharmacy agreed to a $15,000 fine after the Board found it was preparing bulk quantities of Semaglutide without patient-specific prescriptions
  • February 2026 Guidance: The Board published formal guidance establishing that all compounded peptides must be prepared pursuant to a valid patient-specific prescription from a licensed Ohio practitioner
  • License actions: Ohio suspended licenses for clinics found with research-labeled peptide vials in clinical refrigerators — no patient harm required, mere possession in a clinical setting was sufficient

California

California took a legislative approach:

  • Assembly Bill 1887 (effective January 2025): Requires all research peptides shipped to California addresses to include a California-specific disclosure statement on the MSDS, indicating the peptide is not approved for human or animal therapeutic use within state borders
  • Corporate practice of medicine: Novo Nordisk’s August 2025 lawsuits specifically targeted telehealth companies under California’s corporate practice of medicine doctrine, arguing that corporations were improperly steering patient care to compounded Semaglutide
  • Enforcement coordination: California’s Department of Consumer Affairs coordinated with federal agencies on compounding pharmacy investigations

Florida

Florida adopted the most restrictive state framework:

  • License suspensions for possession: Florida regulators suspended clinic licenses for the mere presence of research-labeled vials in clinical refrigerators — no evidence of patient administration required
  • Compounding pharmacy scrutiny: The Florida Board of Pharmacy increased inspection frequency for compounding pharmacies handling peptides
  • GLP-1 enforcement: State attorneys general’s office investigated telehealth firms operating in Florida that continued selling compounded GLP-1 medications after shortage resolutions
  • Practitioner liability: Florida raised the stakes for prescribers by signaling that physicians who facilitate access to compounded peptides outside established regulatory channels face professional discipline

Texas

Texas served as a key venue for both federal and state-level enforcement:

  • Litigation venue: The Outsourcing Facilities Association (OFA) filed a lawsuit against the FDA in Fort Worth challenging the semaglutide shortage resolution
  • Strive v. Lilly/Novo: The antitrust counter-suit against manufacturers was filed in the Western District of Texas
  • Eli Lilly v. Empower: Lilly strategically moved this case from New Jersey to the Southern District of Texas
  • State pharmacy board: Texas Pharmacy Board increased scrutiny of 503A and 503B facilities within the state
  • Empower’s home turf: As a Texas-based compounder, Empower’s conflicts with FDA and manufacturers have drawn state regulatory attention

Impact

  • Patchwork enforcement: No uniform state approach exists — researchers and vendors must understand jurisdiction-specific rules
  • License risk for clinics: The Ohio and Florida approach of suspending licenses for mere possession (not administration) of research peptides in clinical settings raises the stakes dramatically for practitioners
  • California disclosure requirement: Adds compliance burden for vendors shipping to California, even for legitimate research-use products
  • State AG involvement: State attorneys general entering the GLP-1 space means compounders and telehealth firms face enforcement from yet another direction
  • Venue shopping: Texas has emerged as the preferred venue for major peptide-related litigation

What This Means for Researchers

  • Know your state: Peptide legality is increasingly determined at the state level, not just federally
  • Clinics at risk: Practitioners who keep research peptides in clinical settings — even if not administering them — face license suspension in Ohio and Florida
  • California vendors: Any vendor shipping to California must comply with AB 1887 disclosure requirements
  • Multi-state operations: Vendors and telehealth platforms operating across state lines face the most complex compliance landscape
  • See State-Legal-Status for state-by-state reference

Sources